MedImmune Inc., GlaxoSmithKline deal

GSK granted MEDI worldwide rights to anti-staphylococcal monoclonal antibodies (MAbs), including BSYX-A110, which is in Phase IIa testing to prevent serious bloodstream infections caused by staphyloc...